Roche Partners with Zealand Pharma in $5.3 Billion Deal for Obesity Drug Petrelintide

23 posts • ChatGPT (o1)

Updated Mar 12, 2025, 12:01 PM

Roche Holding AG has entered into an exclusive collaboration and licensing agreement with Denmark's Zealand Pharma to co-develop and co-commercialize petrelintide, an experimental weight-loss drug, as part of its expansion into the obesity market. Under the terms of the agreement, Zealand Pharma will receive upfront cash payments of $1.65 billion, with the deal valued at up to $5.3 billion, marking Roche's largest investment in obesity treatments to date. Petrelintide is an amylin analog that has shown promise in weight-loss therapy. The partnership aims to position petrelintide as a foundational therapy for individuals with overweight and obesity, tapping into a market projected to reach $80 billion to $140 billion. The collaboration includes a 50/50 profit-sharing arrangement between the two companies. Following the announcement, Zealand Pharma's stock surged, reflecting investor optimism about the potential of petrelintide with Roche's backing. This deal highlights the intensifying competition in the obesity drug market, with other pharmaceutical companies, such as AbbVie, also securing deals for amylin analogs. Roche's agreement underscores a strategic move to strengthen its obesity pipeline in a rapidly growing field.

More breaking stories on DeepNewz — updated live.

#Roche Holding AG #Denmark #Zealand Pharma #Roche #AbbVie

Will Ukraine agree to give up the rest of Donbas?

US-Iran nuclear deal in 2025?

Will Ukraine agree to give up Russian territory in Kursk?

•

View market suggestions→

Sources

bloomberg.com(3)reuters.com(2)globenewswire.com(2)statnews.com(2)

CHItrader

@CHItraders

$RHHBY Roche Entered a collaboration with Zealand Pharma for an obesity therapy https://t.co/Zpi9pWCRRq

dough

@semodough

Cantor $ZEAL is only up 25% (current market cap: $6.3B), which seems low as it only implies peak sales of petre of $2B and no other pipeline value. think stock will move higher as investors appreciate the opportunity for petrelintide now with Roche’s backing. Good summary Prakhar

Persimmon Tree Investments

@PersimmonTI

$RHHBY — $ZEAL, $xbi Up to $5.3b from $RHHBY to $ZEAL to partner petrelintide, amylin analog, $1.6b upfront. Note that 50/50 split extends to petrelintide x $RHHBY Carmot-acquired GLP1 combo… On the heels of $ABBV deal with Gubra, also for amylin analog, we will see if $ABBV… https://t.co/YJnU6ryV1G